Thu, Jun 26, 2025
[Archive]
Volume 30, Issue 143 (November & December 2022)
J Adv Med Biomed Res 2022, 30(143): 486-492 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Razavi R, Namiranian N, Samet M, Aghaei Meybodi F. Investigating the Therapeutic Effect of β-Interferon and Methylprednisolone on COVID- 19 Patients’Consequence: A Non- Randomized, Double-Blinded, Controlled Study. J Adv Med Biomed Res 2022; 30 (143) :486-492
URL: http://journal.zums.ac.ir/article-1-6495-en.html
URL: http://journal.zums.ac.ir/article-1-6495-en.html
1- Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2- Dept. of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3- Dept. of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ,Dr.Aghaeimeybodi@gmail.com
2- Dept. of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3- Dept. of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ,
Abstract: (30208 Views)
Background and Objective: Due to the severe inflammatory conditions and cytokine storm in COVID-19 disease, corticosteroids are used worldwide as adjunctive therapy for these patients due to their anti-inflammatory effects. However, due to limited and inconsistent information about the effectiveness of this drug, this study aimed to investigate the benefit of combined use of β-interferon and methylprednisolone in patients with COVID-19.
Materials and Methods: 57 patients infected with SARS coronavirus 2 underwent treatment. Laboratory parameters, hospitalization duration, and clinical outcomes in these patients were studied.
Results: Statistical analysis showed no correlation between combination therapy with the hospitalization duration (P=0.22) and mortality (P=0.48). Also, the findings of this study showed that the ESR level in patients receiving combination therapy with methylprednisolone and interferon beta decreased significantly at the end of the intervention (P=0.0001). At the end of the study, the levels of neutrophils (P=0.001) and lymphocytes (P- value=0.0001) in the blood in the interferon group showed a significant change.
Conclusion: This study showed no effect of adding methylprednisolone and interferon beta to the treatment protocol on mortality in the patients.
Full-Text [PDF 393 kb]
(17278 Downloads)
| | Full-Text (HTML) (933 Views)
✅ This study showed no effect of adding methylprednisolone and interferon beta to the treatment protocol on mortality in the patients.
Type of Study: Clinical Trials |
Subject:
Clinical Medicine
Received: 2021/04/11 | Accepted: 2021/08/14 | Published: 2022/10/10
Received: 2021/04/11 | Accepted: 2021/08/14 | Published: 2022/10/10
References
1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. 323(13): 1239-42. [DOI:10.1001/jama.2020.2648] [PMID]
2. Chen N. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223): 507-13. [DOI:10.1016/S0140-6736(20)30211-7]
3. Zhou F, Ting YU, Ronghi Du, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;1054-62 [DOI:10.1016/S0140-6736(20)30566-3]
4. Luo P. Tocilizumab treatment in COVID‐19: A single center experience. J Med Virol. 2020. 92(7): 814-18. [DOI:10.1002/jmv.25801] [PMID] [PMCID]
5. Wang Y. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Trans Target The. 2020. 5(1): 1-3. [DOI:10.1038/s41392-020-0158-2] [PMID] [PMCID]
6. Whitlock RP. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet. 2015; 386(10000): 1243-53. [DOI:10.1016/S0140-6736(15)00273-1]
7. Arabi YM, Chrousos GP, Meduri GU. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. 2020, Springer. [DOI:10.1007/s00134-020-06223-y] [PMID] [PMCID]
8. Zhou W. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020. 5(1):1-3. [DOI:10.1038/s41392-020-0127-9] [PMID] [PMCID]
9. Marik PE. Steroids for sepsis: yes, no or maybe. J Thoracic Disease. 2018. 10(Suppl 9): S1070. [DOI:10.21037/jtd.2018.04.35] [PMID] [PMCID]
10. Campaign SS. International guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017; 43(3): 304-77. [DOI:10.1007/s00134-017-4683-6] [PMID]
11. Stockman LJ, R. Bellamy, Garner P. SARS: systematic review of treatment effects. PLoS Med, 2006. 3(9): e343. [DOI:10.1371/journal.pmed.0030343] [PMID] [PMCID]
12. Dieleman JM. Prophylactic corticosteroids for cardiopulmonary bypass in adults. Cochrane Database of Systematic Reviews, 2011(5). [DOI:10.1002/14651858.CD005566.pub3] [PMID]
13. Wu, C., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA internal medicine, 2020; 1;180(7):934-43
14. Hu Y, Wang T, Hu Z, Wang X, Zhang Z, Li L, et al. Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience. Biomed & Pharmacother. 2020; 130:110529. [DOI:10.1016/j.biopha.2020.110529] [PMID] [PMCID]
15. Minneci PC, Deans KJ, Eichacker PQ, Natanson C. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clinical microbiology and infection, 2009. 15(4): 308-318. [DOI:10.1111/j.1469-0691.2009.02752.x] [PMID] [PMCID]
16. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating sepsis. Cochrane database of systematic reviews, 2015(12). [DOI:10.1002/14651858.CD002243.pub3] [PMID] [PMCID]
17. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA. 2009. 301(22): 2362-75. [DOI:10.1001/jama.2009.815] [PMID]
18. Jeronimo CM, Farias ME, Val FF, Sampaio VS, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial.Clin Infect Dis.2020; ciaa1177
19. Arabi YM, Mandourah Y, Al-Hameed F. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6): 757-67. [DOI:10.1164/rccm.201706-1172OC] [PMID]
20. Steinberg K. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrime (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006; 354:1671-84. [DOI:10.1056/NEJMoa051693] [PMID]
21. Torres A, Sibila O, Ferrer M. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015; 313(7): 677-86. [DOI:10.1001/jama.2015.88] [PMID]
22. Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020; 81(1):e13-20 [DOI:10.1016/j.jinf.2020.03.062] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
